Objective: Interleukin-18 (IL-18) is a cytokine with proinflammatory and proatherogenic properties, which might be associated with the development of insulin resistance. In contrast, adiponectin, a protein secreted by adipose tissue, might exert insulinsensitizing and antiatherogenic effects. The aim of the present study was to analyze the association between serum IL-18 and adiponectin in lean and obese subjects, in relation to insulin resistance. Design: Cross-sectional study. Subjects: One hundred and thirty individuals, 62 lean (body mass index (BMI)o25 kg/m 2 , 30 men and 32 women) and 68 with overweight or obesity (BMI425 kg/m 2 , 24 men and 44 women), with normal glucose tolerance and without concomitant diseases. Measurements: Oral glucose tolerance test, euglycemic hyperinsulinemic clamp, serum concentrations of IL-18, IL-6, soluble tumor necrosis factor-a receptors and adiponectin. Results: Obese subjects had lower insulin sensitivity (M value, P ¼ 0.00029) and serum adiponectin (P ¼ 0.01) and higher levels of serum IL-18 (P ¼ 0.00055). Circulating IL-18 was negatively related to adiponectin (r ¼ À0.31, P ¼ 0.00027) and insulin sensitivity (r ¼ À0.33, P ¼ 0.00012). Subgroup analysis revealed that these associations were present in the obese (adiponectin, r ¼ À0.38, P ¼ 0.0014; M, r ¼ À0.29, P ¼ 0.016), but not in lean individuals (r ¼ À0.17, P ¼ 0.18 and r ¼ À0.20, P ¼ 0.12, respectively). Association of IL-18 with adiponectin remained significant after adjustment for other estimated parameters, including insulin sensitivity. Also, relationship between IL-18 and insulin sensitivity was independent of other estimated parameters. Conclusion: Serum IL-18 is inversely related to serum adiponectin, independently of insulin resistance. The relationships of IL-18 with adiponectin and insulin sensitivity are influenced by the presence of overweight/obesity.
Introduction
There is growing evidence that low-grade chronic inflammation might lead to the development of both insulin resistance and atherogenesis. 1, 2 Interleukin-18 (IL-18) is a proinflammatory cytokine, known also for its proatherogenic properties. It is a predictor of coronary events in healthy, middle-aged men 3 and a predictor of cardiovascular death in stable and unstable angina. 4 Recently, a few studies suggested a possible metabolic function of IL-18. It was demonstrated that IL-18 was expressed in adipocytes; 5, 6 however, the secretion of this cytokine from adipocytes was very low in one study 5 and not detected in another. 6 Increased IL-18 levels were found in obesity, 7 polycystic ovary syndrome, 8 metabolic syndrome 9 and type 2 diabetes. [10] [11] [12] Elevated IL-18 concentration was also found to be an independent predictor of the development of type 2 diabetes. 13 In line with the above findings, recent studies provided an evidence that IL-18 is directly associated with insulin resistance. 8, 14, 15 In contrast, adiponectin, a protein secreted by adipose tissue, has insulin-sensitizing, antiatherogenic and antiinflammatory effects. 16, 17 Circulating adiponectin concentration is decreased in obesity, type 2 diabetes, 18 lean offspring of type 2 diabetic subjects 19 and is positively related to insulin action. 18, 19 The interrelationship between IL-18 and adiponectin has not been reported so far. The aim of the present study was to analyze the association between serum IL-18 and adiponectin in lean and obese subjects, in relation to insulin resistance.
Subjects and methods

Subjects
A total of 130 subjects, 54 men and 76 women, participated in the present study. In that group, 62 subjects were lean (body mass index (BMI) o25 kg/m 2 , 30 men and 32 women) and 68 were overweight or obese (BMI 425 kg/m 2 , 24 men and 44 women). All participants had no morbid obesity (BMI 440 kg/m 2 ), cardiovascular disease, hypertension, infections or any other serious medical problems. Also, subjects had no previous history of type 2 diabetes or impaired glucose tolerance and all had fasting plasma glucose levels below 6.1 mmol/l. Subjects underwent an oral glucose tolerance test and they all had normal glucose tolerance according to the WHO criteria. All subjects were non-smokers and were not taking any anti-inflammatory drugs (within previous 3 months) or drugs known to affect carbohydrate and lipid metabolism. Before entering the study, physical examination and appropriate laboratory tests were performed. Analyses were performed after an overnight fast. The study protocol was approved by the Ethics Committee of Medical University of Bialystok, Poland. All subjects gave written informed consent before entering the study.
Anthropometric measurements
BMI was calculated as body weight in kilograms divided by height in meters squared (kg/m 2 ). The waist-to-hip ratio (WHR) was estimated. Percent of body fat was assessed by bioelectric impedance analysis using the Tanita TBF-511 Body Fat Analyzer (Tanita Corp., Tokyo, Japan).
Insulin sensitivity
Insulin sensitivity was evaluated by euglycemic hyperinsulinemic clamp technique according to DeFronzo et al. 20 On the morning of the study, two venous catheters were inserted into antecubital veins, one for the infusion of insulin and glucose and the other in the contralateral hand for blood sampling, that hand was heated to approximately 601C. Insulin (Actrapid HM, Novo Nordisk, Copenhagen, Denmark) was given as a primed-continuous intravenous infusion for 2 h at 40 mU/m 2 /min resulting in constant hyperinsulinemia of approximately 550 pmol/l. Arterialized blood glucose was obtained every 5 min and 20% dextrose (1.11 mol/l) infusion was adjusted to maintain plasma glucose levels at 5.0 mmol/l. The glucose infusion rate approached stable values during final 40 min of the study and the rate of whole-body glucose uptake (M value) was calculated as the mean glucose infusion rate from 80 to 120 min, corrected for glucose space and normalized per kilogram of fat-free mass (ffm).
Biochemical analyses
Fasting blood samples were also taken from the antecubital vein before the beginning of the clamp for the determination of serum lipids, IL-18, IL-6, soluble forms of tumor necrosis factor (TNF)-a receptors (sTNFR1 and sTNFR2), adiponectin and C-reactive protein (CRP). Samples were frozen at À701C until analyses.
Plasma glucose was measured immediately by the enzymatic method using glucose analyzer (YSI 2300 STAT Plus, Yellow Springs, OH, USA). Serum insulin was measured with the monoclonal immunoradiometric assay (Medgenix Diagnostics, Fleunes, Belgium). Serum total and high-density lipoprotein (HDL)-cholesterol and triglycerides (TG) were assessed by the enzymatic methods (Cormay, Warsaw, Poland). Serum low-density lipoprotein-cholesterol was calculated according to Friedewald's formula.
Serum IL-18 concentration was measured with the enzyme-linked immunosorbent assay (ELISA) Kits (Quantikine, R&D Systems Inc., Minneapolis, MN, USA) with the detection limit of the method below 12.5 pg/ml and the intraassay and inter-assay coefficient of variances (CVs) below 11%. Serum adiponectin was measured with radioimmunoassay Kit (Linco Research Inc., St Charles, MO, USA) with the detection limit 1 ng/ml and with intra-assay and inter-assay CVs below 6.3 and 9.5%, respectively. Serum IL-6 was estimated with the high-sensitive ELISA (Quantikine HS, R&D Systems Inc.) with the detection limit 0.039 pg/ml and with intra-assay and inter-assay CVs below 6.9 and 9.6%, respectively. Serum sTNFR1 and sTNFR2 were determined with the enzyme amplified sensitivity immunoassay (EASIA) kits (BioSource Europe, Nivelles, Belgium). The minimum detectable concentration was 0.05 ng/ml for sTNFR1 and 0.1 ng/ml for sTNFR2. The intra-assay and inter-assay CVs for both receptors were below 6.5 and 9%, respectively. Serum CRP was estimated with the high-sensitive ELISA kit (highsensitive CRP (hs-CRP); Euroimmun, Luebeck, Germany) with the detection limit of 0.8 ng/ml and with intra-assay and inter-assay CVs below 7.8%.
Statistical analysis
The statistics were performed with the STATISTICA 6.0 program. Differences between the groups were evaluated with Mann-Whitney U-test (for variables, which did not have normal distribution, i.e. M value, IL-18, IL-6, adiponectin, fasting and postload insulin, TG) or with an unpaired Student's t-test (for other variables). Relationships between IL-18 and other variables were assessed with the Spearman rank R analysis and with multiple regression analysis. The level of significance was accepted at P-value o0.05.
Results
The clinical characteristics of the study group are shown in Table 1 . Obese subjects had lower insulin sensitivity (P ¼ 0.00029) and serum adiponectin (P ¼ 0.01) and higher levels of serum IL-18 (P ¼ 0.00055). Table 2 shows the correlations between serum IL-18 and other estimated parameters in the whole studied group. Cross-sectionally, IL-18 was positively related to BMI, WHR, percent of body fat, fat mass and ffm, fasting insulin, TG, and hs-CRP, and negatively to insulin sensitivity, adiponectin ( Figure 1 ) and HDL-cholesterol.
Subgroup analysis revealed that the associations of IL-18 with adiponectin and insulin sensitivity were present in the obese (adiponectin, r ¼ À0.38, P ¼ 0.0014; M, r ¼ À0.29, P ¼ 0.016), but not in lean individuals (r ¼ À0.17, P ¼ 0.18 and r ¼ À0.20, P ¼ 0.12, respectively). Similarly, adiponectin was related to M value in the whole group (r ¼ 0.18, P ¼ 0.043) and within the subgroup of obese (r ¼ 0.24, P ¼ 0.049), but not lean subjects (r ¼ À0.01, P ¼ 0.93).
In multiple regression analysis, association between IL-18 and adiponectin remained significant after adjustment for age, sex, BMI, fasting and postload glucose and insulin, insulin sensitivity, total and HDL-cholesterol, TG, sTNFR1, sTNFR2, IL-6 and hs-CRP in the whole group (b ¼ À0.20, P ¼ 0.038) and in obese individuals (b ¼ À0.38, P ¼ 0.0052). Also, in the whole group, relationship of IL-18 with M value was still present after adjusting for other estimated parameters, including adiponectin (b ¼ À0.31, P ¼ 0.001). In contrast, relationship between adiponectin and insulin sensitivity disappeared after controlling for IL-18 (b ¼ 0.076, P ¼ 0.38).
Discussion
In the present study, we demonstrated an increase in serum IL-18 concentration in obese subjects. This is consistent with previous reports. 7, 8 We also observed a significant inverse correlation between serum IL-18 and insulin sensitivity. Thus, our report, which utilized euglycemic hyperinsulinemic clamp technique, is in agreement with previous data, which used indirect indices of insulin action 8, 15 or minimal model analysis. 14 The new observation coming from the present study is an inverse relationship between IL-18 and adiponectin. As mentioned, although adiponectin is synthesized in adipose tissue, its levels are decreased in obesity. 18 The reason of this decrease remains unknown and it is speculated that cytokines secreted by adipocytes might inhibit adiponectin synthesis and secretion. In the context of our findings, it is possible that IL-18 might be the factor inhibiting adiponectin secretion from adipose tissue and thus might contribute to hypoadiponectinemia in obesity. Findings of multiple regression analysis, which show that the association between IL-18 and adiponectin is independent of IL-6 and soluble forms of TNF-a receptors (indicators of local TNF-a action), strengthen this hypothesis. On the other hand, adiponectin has anti-inflammatory properties, and one cannot rule out the hypothesis, that decrease in adiponectin is a primary abnormality, which leads to an increased proinflammatory cascade, including increase in IL-18 secretion. So far, in vitro studies examining interrelationships between IL-18 and adiponectin are lacking. 22 and it is possible that, in these conditions, some confounding factors influenced this association, present in the group of young and apparently healthy individuals. Independent associations of IL-18 with insulin sensitivity and adiponectin indicate that IL-18 is linked with metabolic processes in multiple pathways. In contrast, relationship between adiponectin and insulin sensitivity was no longer significant after controlling for IL-18. This finding suggests that insulin-sensitizing actions of adiponectin might be influenced by proinflammatory factors.
Our results stress the importance of overweight/obesity for the revealing of associations between IL-18 and adiponectin and between both factors and insulin action. The present study provides some new data regarding the mechanisms linking obesity with insulin resistance and, if we take into account a different impact of both adipocytokines on atherogenesis, also with cardiovascular disease.
In conclusion, serum IL-18 is inversely related to serum adiponectin, independently of insulin resistance. The relationships of IL-18 with adiponectin and insulin sensitivity are influenced by the presence of overweight/obesity.
